Vision2Voice Wins 2019 Better Business Bureau Integrity Award

A letter of thanks from Vision2Voice President Dan Rehal:

In Vision2Voice’s 12th year of business, I find myself thinking about our biggest achievements. Time and again it comes back to our relationships and the values we share with you as our clients.  

There’s no better validation of our commitment to Integrity and Ethics than being recognized by the Better Business Bureau in a big way. Vision2Voice has just received BBB’s 2019 Integrity Award; our second win since first receiving the award in 2014. The only Medical Communications Agency to have been awarded even once. I’m writing this letter to thank all of you for making this possible. Our shared values and commitment from our relationships with people like you is what has made V2V a thriving and successful organization committed to improving the lives of patient care. We wouldn’t be in business if there weren’t people with commitment and dedication like yours in healthcare.  

Of all the business awards, I can genuinely say this award means more to me than any. The reason is because this award focuses on how organizations conduct their business. Doing things the right way. In the words of Henry Ford “A business that only makes money is a poor kind of business.”  

I am proud to say that, together, we’ve made an impact in the lives of patients. We’ve done it with integrity. That’s something worth celebrating.  

Daniel J. Rehal,
President, Vision2Voice

Recent Posts

Man in suit holding back dominos

Will Your Launch Strategy Succeed or Fail?

The Challenge: A Faster, More Complex Launch Environment In today’s pharmaceutical market, strong science is the foundation, but it doesn’t always guarantee a successful launch....

Read More
Story 2

Industry Insights – June 2026

From evolving China deal dynamics and prolonged job searches to the growing push for AI-driven drug repurposing, explore how shifts in BioPharma are redefining innovation,...

Read More
FDA Commissioner Marty Makary, M.D.

Industry Insights – May 2026

Biosimilars are gaining U.S. momentum even as patent thickets keep triggering legal fights, small biotechs are feeling the pressure of the FDA’s faster-moving approval environment,...

Read More